Zimbabwe has rejected a significant US health deal worth 367 million US dollars (£272m) over five years due to Washington's insistence on sensitive data.
This move was revealed after a internal memorandum from December was leaked, revealing that Head of State Emmerson Mnangagwa felt the deal was "skewed".
An official spokesperson has since explained that the US was requesting genetic material for scientific study and commercial purposes while refused to guarantee the benefits from future medical innovations.
"We must now begin the difficult and regrettable process of scaling back our health aid in Zimbabwe," stated US ambassador to Zimbabwe Pamela Tremont publicly.
The US Embassy indicated the US had furnished over $1.9bn as health assistance to Zimbabwe over the last twenty years.
A physicians' group in Zimbabwe has urged continued talks to secure a agreement acceptable to both sides so the country's vital HIV programme can proceed.
Broader Implications
Zimbabwe's decision comes after a similar situation in neighbouring Kenya, where a high court blocked a related health funding agreement following legal challenges were filed about the safety of Kenyans' medical information.
After returning to office recently, US President Donald Trump has slashed overseas assistance and closed the US Agency for International Development (USAID).
USAID had managed aid for the US government, but Trump claimed its expenditure was "wasteful" and his government was pursuing direct bilateral agreements to enhance openness and responsibility.
According to statements, Sixteen nations in Africa have to date agreed to these new health pacts, representing over $18.3bn in committed funds.
Specifics of the Rejected Deal
The funds for Zimbabwe was intended to supported "combating HIV/Aids, TB, malaria, healthcare for mothers and children, and preparing for epidemics".
"We believe this cooperation could have provided significant advantages for the people of Zimbabwe, particularly the 1.2 million men, women and children currently receiving antiretroviral therapy through US-supported initiatives," Tremont commented.
However, government spokesperson Nick Mangwana said the arrangement was "unfair".
"Zimbabwe was being asked to share its biological resources and data over an extended period, without any corresponding promise of benefiting from any scientific breakthroughs – like new medicines or tests – that could be developed from that provided information," he stated.
"Put simply, our nation would provide the raw materials for medical research with no certainty that the resulting innovations would be accessible to our population if a future pandemic emerge."
Sovereignty and International Frameworks
Mangwana further said that the American exit from the World Health Organization (WHO) and its pursuit of one-on-one deals were disrupting structures already established via the international organization.
The spokesperson gave as an example its Pathogen Access and Benefit Sharing scheme created to deal with future pandemics.
"This mechanism is designed to guarantee that when a country provides its samples, the benefits – such as vaccines and treatments – are shared equitably, not monopolised exclusively by those with the funds to develop them."
These objections regarding the US deal "are not meant as anti-American sentiment," he added.
"We encourage further dialogue with our US partners on how future co-operation might be arranged in a manner that honours the sovereignty and interests of each country."
Health Experts Response
The Zimbabwe College of Public Health Physicians (ZCPHP) said it acknowledged the government's concerns, but recommended that negotiations should continue considering a large portion of the country's HIV programmes were funded by foreign aid.
"If technical issues arise, including those relating to information security or implementation frameworks, these can often be resolved via detailed discussion and mutually agreed protections," the group commented.
This impasse emphasises the complex tensions between accepting crucial international aid and protecting a country's data in an increasingly interconnected world.